Cargando…
Cost Effectiveness of DCISionRT for Guiding Treatment of Ductal Carcinoma in Situ
The DCISionRT test estimates the risk of an ipsilateral breast event (IBE) in patients with ductal carcinoma in situ (DCIS) as well as the benefit of adjuvant radiation therapy (RT). We determined the cost-effectiveness of DCISionRT using a Markov model simulating 10-year outcomes for 60-year-old wo...
Autores principales: | Raldow, Ann C, Sher, David, Chen, Aileen B, Punglia, Rinaa S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083239/ https://www.ncbi.nlm.nih.gov/pubmed/32211582 http://dx.doi.org/10.1093/jncics/pkaa004 |
Ejemplares similares
-
The Clinical Utility of DCISionRT(®) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery
por: Shah, Chirag, et al.
Publicado: (2021) -
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS)
por: Punglia, Rinaa S, et al.
Publicado: (2018) -
DCision-making in tumors governs T cell anti-tumor immunity
por: Alfei, Francesca, et al.
Publicado: (2021) -
Prediction Models and Decision Aids for Women with Ductal Carcinoma In Situ: A Systematic Literature Review
por: Schmitz, Renée S. J. M., et al.
Publicado: (2022) -
AKT1(low) quiescent cancer cells in ductal carcinoma in situ of the breast
por: Kabraji, Sheheryar, et al.
Publicado: (2019)